CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
工程化改造 CAR-T 细胞以增强疗效与安全性
英文原题：Engineering CAR T cells for enhanced efficacy and safety.
查看英文原题
Engineering CAR T cells for enhanced efficacy and safety.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管嵌合抗原受体（CAR）T细胞疗法治疗血液系统恶性肿瘤取得成功，但其更广泛应用仍面临两大挑战：对实体瘤疗效有限，以及非特异性毒性。为应对这些问题，研究者采用合成生物学方法开发多种优化策略。本文综述近期CAR及其他非CAR分子的改进，旨在增强CAR-T 细胞疗效和安全性，并重点介绍不同类型的可诱导CAR-T 细胞开发，这些细胞可由环境信号和/或外部刺激控制。上述进展正推动CAR-T 疗法迈向更安全、更广泛的应用，尤其有望拓展至实体瘤。
展开英文摘要原文
Despite its success in treating hematologic malignancies, chimeric antigen receptor (CAR) T cell therapy faces two major challenges which hinder its broader applications: the limited effectiveness against solid tumors and the nonspecific toxicities. To address these concerns, researchers have used synthetic biology approaches to develop optimization strategies. In this review, we discuss recent improvements on the CAR and other non-CAR molecules aimed to enhance CAR T cell efficacy and safety.
We also highlight the development of different types of inducible CAR T cells that can be controlled by environmental cues and/or external stimuli. These advancements are bringing CAR T therapy one step closer to safer and wider applications, especially for solid tumors.
论文信息
- 作者
- Wu Y、Huang Z、Harrison R、Liu L、Zhu L、Situ Y、Wang Y
- 第一作者单位
- Institute of Engineering in Medicine, University of California, San Diego, La Jolla, California 92093, USA.United States
- 文献类型
- 综述
- 期刊
- APL bioengineering2022 Mar
- 原文标识
- PubMed 35071966 · DOI 10.1063/5.0073746
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →